Circio invites to R&D and corporate update webcast on 4 December 2024

28 Nov 2024 14:33 CET

· CEO Dr. Erik D Wiklund will provide a company update and information related
to the upcoming warrant exercise period
· CTO Dr. Thomas B Hansen will present the most recent circVec in vitro and in
vivo data and an overview of Circio´s R&D strategy

Oslo, Norway 28 November 2024 - Circio Holding ASA (OSE: CRNA), a biotechnology
company developing powerful circular RNA technology for next generation nucleic
acid medicine, invites to a live webcast at 10:00am CEST on Wednesday 4 December
2024. In the webcast, Circio management will provide a corporate update and
showcase the latest developments for the circVec platform technology. Practical
information relating to the warrant exercise period in connection with the
rights issue completed during June-July 2024 will also be provided.


Presenters:

CEO Dr. Erik Digman Wiklund
CTO Dr. Thomas Birkballe Hansen

Time: 10:00 CEST on 4 December 2024

Click here to access Teams webcast (https://teams.microsoft.com/l/meetup
-join/19%3ameeting_YWU3YjYwMDktMWJmOC00NTdjLWFmMjYtOTUyMWNjNzJlNmJl%40thread.v2/
0
?context=%7b%22Tid%22%3a%2266b0661a-3ec3-48a8-a966
-5b0cce82b3fe%22%2c%22Oid%22%3a%223f5f84b0-5521-4c04-bd8a-e185546abe04%22%7d)
Meeting ID: 349 042 796 001
Passcode: 2PM24NF6


Questions can be submitted in advance by email to: erik.wiklund@circio.com or
directly in the live webcast

A recording of the webcast will be made available on the Circio
webpage (http://www.circio.com)

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Neil Hunter - Hunter PR
Phone:+44 7821 255568 (http://tel:+447821255568)
Email: neiljameshunter@gmail.com

About Circio

Building next generation RNA technology for nucleic acid medicine

Circio Holding ASA is a biotechnology company developing powerful circular RNA
vector expression technology for next generation nucleic acid medicine.

Circio has established a unique circular RNA (circRNA) vector expression
platform for novel DNA, RNA and viral therapeutics. The proprietary circVec
technology is based on a modular genetic cassette design for efficient
biogenesis of multifunctional circRNA inside cells, which can be deployed in
multiple therapeutic settings, including genetic medicine, cell therapy and
chronic disease. The circVec platform has demonstrated up to 15-fold enhanced
and more significantly more durable protein expression vs. classic mRNA vector
systems and has the potential to become a new gold-standard platform technology
for nucleic acid and viral therapeutics in the future. The circRNA R&D
activities are being conducted by the wholly owned subsidiary Circio AB based at
the Karolinska Institute in Stockholm, Sweden.

In addition, Circio is developing a pan-RAS cancer vaccine, TG01, targeting KRAS
driver mutations. TG01 is currently being tested in two clinical trials: RAS
-mutated pancreatic and lung cancer in the USA and multiple myeloma in Norway.
These studies are being run through academic and industry collaborative
networks, supported by prestigious research grants from Innovation Norway and
the Norwegian Research Council, creating read-outs and future optionality for
the program at low cost to Circio.

More information:
Access the news on Oslo Bors NewsWeb site